Haemopoietic-cell transplantation (HCT) is an intensive therapy used to treat high-risk haematological malignant disorders and other life-threatening haematological and genetic diseases. The main complication of HCT is graftversus-host disease (GVHD), an immunological disorder that aff ects many organ systems, including the gastrointestinal tract, liver, skin, and lungs. The number of patients with this complication continues to grow, and many return home from transplant centres after HCT requiring continued treatment with immunosuppressive drugs that increases their risks for serious infections and other complications. In this Seminar, we review our understanding of the risk factors and causes of GHVD, the cellular and cytokine networks implicated in its pathophysiology, and current strategies to prevent and treat the disease. We also summarise supportive-care measures that are essential for management of this medically fragile population.
Introduction
The number of allogeneic haemopoietic-cell transplantations (HCTs) continues to rise, with more than 25 000 procedures undertaken annually. The graft-versusleukaemia or graft-versus-tumour eff ect during this procedure eff ectively eradicates many haema tological malignant diseases. 1 Development of novel strategies that use donor leucocyte infusions, non-myeloablative conditioning, and umbilical-cord blood transplantation has helped expand the indications for allogeneic HCT over the past few years, especially for older patients. 2 Improvements in infectious prophylaxis, immunosuppressive treatments, suppor tive care, and DNA-based tissue typing have also contributed to enhanced outcomes after the technique. 1 Yet, the major complication of allogeneic HCT-graft-versus-host disease (GVHD)-remains lethal and limits use of this important procedure. 2 In view of current trends, the number of transplants from unrelated donors is expected to double within the next 5 years, substantially increasing the population of patients with GVHD. In this Seminar, we review advances made in identifi cation of genetic risk factors and pathophysiology of this major HCT complication and its prevention, diagnosis, and treatment. 50 years ago, Billingham formulated three requirements for development of GVHD: (1) the graft must contain immunologically competent cells; (2) the recipient must express tissue antigens that are not present in the transplant donor; and (3) the patient must be incapable of mounting an eff ective response to eliminate the transplanted cells. 3 We know now that the immunologically competent cells are T cells and that GVHD can develop in various clinical settings when tissues containing T cells (blood products, bone marrow, and solid organs) are transferred from one person to another who is not able to eliminate those cells. 4, 5 Patients whose immune systems are suppressed and who receive white blood cells from another individual are at especially high risk for the disease.
Cause and clinical features
GVHD arises when donor T cells respond to genetically defi ned proteins on host cells. The most important proteins are human leucocyte antigens (HLAs), 2, 6, 7 which are highly polymorphic and are encoded by the major histocompatibility complex (MHC). Class I HLA (A, B, and C) proteins are expressed on almost all nucleated cells of the body at various densities. Class II proteins (DR, DQ, and DP) are mainly expressed on haemopoietic cells (B cells, dendritic cells, and monocytes), but their expression can be induced on many other cell types after infl ammation or injury. High-resolution DNA typing of HLA genes with PCR-based techniques has now largely replaced earlier methods. The frequency of acute GVHD is directly related to the degree of mismatch between HLA proteins, 8, 9 and thus ideally, donors and recipients are matched at HLA A, B, C, and DRB1 (referred to as 8/8 matches), but mismatches can be tolerated for umbilical-cord blood grafts (see Clinical features of acute GVHD). [10] [11] [12] Despite HLA identity between a patient and donor, about 40% of recipients of HLA-identical grafts develop systemic acute GVHD that needs treatment with high-dose steroids. This disorder is due to genetic diff erences that lie outside the HLA loci and that encode proteins referred to as minor histocompatibility antigens. Some minor histocompatibility antigens, such as HY and HA-3, are expressed on all tissues and are targets for both GVHD and graft-versus-leukaemia. 13 Others, such as HA-1 and HA-2, are expressed most abundantly on haemopoietic cells (including leukaemic cells) and could, therefore, induce an enhanced graft-versus-leukaemia eff ect with diminished GVHD.
Polymorphisms in both donors and recipients of cytokines that have a role in the classic cytokine storm of GVHD (see Pathophysiology of acute GVHD) have been implicated as risk factors for the disorder. 15 Tumour necrosis factor (TNF) α, interleukin 10, and interferon γ variants have correlated with GVHD in some, but not all, studies. [16] [17] [18] Genetic polymorphisms of proteins connected with innate immunity, such as nucleotide oligomerisation domain 2 and keratin 18 receptors, have also been associated with the disorder. [19] [20] [21] [22] Future strategies to identify the best possible transplant donor will probably incorporate both HLA and non-HLA genetic factors.
Clinical features of acute GVHD
On the basis of early work, acute GVHD was defi ned as arising before day 100 post-transplant, whereas chronic disease happened after that time. [23] [24] [25] This defi nition is far from satisfactory, and a National Institutes of Health classifi cation includes late-onset acute GVHD (after day 100) and an overlap syndrome with features of both acute and chronic disorder. 26, 27 Late-onset acute GVHD and the overlap syndrome arise with greater frequency after reduced-intensity conditioning, an increasingly widespread technique (see Prevention of GVHD). Panel 1 shows the clinical manifestations of acute GVHD. In a comprehensive review, Martin and colleagues noted that at onset of acute GVHD, aff ected regions included skin (81% of patients), gastrointestinal tract (54%), and liver (50%). 23 Skin is most frequently aff ected and is usually the fi rst organ involved, generally coinciding with engraftment of donor cells. The characteristic maculopapular rash is pruritic and can spread throughout the body, sparing the scalp (fi gure 1). In severe cases the skin can blister and ulcerate. 28 Apoptosis at the base of epidermal rete pegs is a characteristic pathological fi nding. Other features include dyskeratosis, exocytosis of lymphocytes, satellite lymphocytes adjacent to dyskeratotic epidermal keratinocytes, and perivascular lymphocytic infi ltration in the dermis. 29, 30 Gastrointestinal-tract involvement of acute GVHD usually presents as diarrhoea but can also include vomiting, anorexia, abdominal pain, or a combination when severe. 29 Diarrhoea in GVHD is secretory and usually voluminous (>2 L per day). Bleeding, which has poor prognosis, happens as a result of mucosal ulceration, 31 but patchy involvement of mucosa generally leads to a normal appearance on endoscopy. 32 Radiological fi ndings of the gastrointestinal tract include luminal dilatation with thickening of the wall of the small bowel (ribbon sign on CT) and air or fl uid levels suggestive of an ileus. 28 Histological features include patchy ulcerations, apoptotic bodies in the base of crypts, crypt abscesses, and loss and fl attening of surface epithelium. 33 Liver disease caused by GVHD can be diffi cult to distinguish from other causes of liver dysfunction after bone-marrow transplantation, such as veno-occlusive disease, toxic drug eff ects, viral infection, sepsis, or iron overload. The histological features of hepatic GVHD are endothelialitis, lymphocytic infi ltration of the portal areas, pericholangitis, and bile-duct destruction. 34, 35 However, biopsy specimens of liver are taken rarely because thrombocytopenia early after transplantation greatly increases the risks of the biopsy procedure, making the diagnosis of GVHD one of exclusion.
Severity of acute GVHD is ascertained by the extent of involvement of the three main target organs. Overall grades are I (mild), II (moderate), III (severe), and IV (very severe). Severe GVHD has poor prognosis, with 25% long-term survival (5 years) for grade III disease and 5% for grade IV. Prevalence of acute GVHD is directly related to the degree of mismatch between HLA proteins. It ranges from 35-45% in recipients of full-matched sibling donor grafts 8, 9 to 60-80% in people receiving one-antigen HLA-mismatched unrelated-donor grafts. 6, [37] [38] [39] The same amount of mismatch causes diminished GVHD with umbilical-cord blood grafts, and frequency of acute GVHD is low after transplantation of partly matched umbilical-cord blood units (35-65%).
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Clinical features of chronic GVHD
Chronic GVHD is the major cause of late non-relapse death after HCT. 40 Its presentation can be progressive (active or acute GVHD merging into chronic), quiescent (acute disease that resolves completely but is followed later by chronic), or de novo. Older recipient age and a history of acute GVHD are the greatest risk factors for chronic disease. 41 Therefore, strategies for acute GVHD prevention could help to prevent chronic disease. Panel 2 shows that manifestations of chronic GVHD are somewhat protean and typically of an autoimmune nature. Clinical signs are generally seen fi rst in the buccal mucosa (fi gure 2). New consensus criteria for diagnosis and staging of chronic GVHD have been developed. 26 
Pathophysiology of acute GVHD
Two important principles should be considered with respect to the pathophysiology of acute GVHD. First, the disease is indicative of exaggerated but typical infl ammatory mechanisms mediated by donor lymphocytes infused into the recipient, in whom they function appropriately in view of the foreign environment they encounter. Second, the recipient's tissues that stimulate donor lymphocytes have usually been damaged by underlying disease, previous infections, and the transplant conditioning regimen. 29 As a result, these tissues produce molecules such as proinfl ammatory cytokines and chemokines, which increase expression of key receptors on antigen-presenting cells (APCs), thereby enhancing cross-presentation of polypeptide proteins (eg, minor histocompatibility antigens) to the donor immune cells that mediate GVHD. [42] [43] [44] [45] Mouse models have been central to identifi cation and understanding of pathophysiological mechanisms of GVHD, and work undertaken in dogs has been vital for development of clinically useful strategies for GVHD prophylaxis and treatment advances in donor leucocyte infusions. 36, 46, 47 Largely on the basis of these experimental data, progression of acute GVHD can be summarised in three sequential steps or phases: (1) activation of APCs; (2) donor T-cell activation, proliferation, diff erentiation, and migration; and (3) target tissue destruction (fi gure 3).
The fi rst step entails activation of APCs by the underlying disease and the HCT conditioning regimen. Damaged host tissues respond by producing so-called danger signals, including proinfl ammatory cytokines (eg, TNFα and interleukins 1 and 6), chemokines, and amplifi ed expression of adhesion molecules, MHC antigens, and costimulatory molecules on host APCs. 42, [48] [49] [50] Findings of a report showed that 1 week after HCT, increased amounts of TNFα receptor 1-a surrogate marker for TNFα-correlated strongly with later development of GVHD. 51 Injury to the gastrointestinal tract from conditioning is especially important because it allows for systemic translocation of additional infl ammatory stimuli, such as microbial products including lipopolysaccharide or other pathogen-associated molecular patterns, that further enhance activation of host APCs. 49 The secondary lymphoid tissue in the gastrointestinal tract is probably the initial site of interaction between activated APCs and donor T cells. 52 These observations have led to an important clinical strategy to diminish acute GVHD by reducing the intensity of the conditioning regimen. 53, 54 Experimental GVHD can also be decreased by manipulation of distinct subsets of APCs. 55, 56 Furthermore, non-haemopoietic stem cells, such as mesenchymal stromal cells, can reduce allogeneic T-cell responses and ameliorate GVHD, although the mechanism for such inhibition remains unclear. 57 The idea that amplifi ed activation of host APCs increases the risk for acute GVHD unifi es several seemingly disparate clinical associations with that risk, such as advanced stages of malignant disease, more intense transplant conditioning regimens, and history of viral infection. APCs detect infections with receptors on their cell surfaces, such as Toll-like receptors, which recognise conserved molecular patterns of microbes. 27, 58 Toll-like receptors specifi c for viral DNA or RNA activate APCs and could boost GVHD, providing a potential mechanistic basis for enhanced disease associated with viral infections such as cytomegalovirus. 59 The core of the graft-versus-host reaction is the second step, in which donor T cells proliferate and diff erentiate in response to host APCs (fi gure 3). The danger signals generated in the fi rst phase augment this activation, at least in part, by increasing expression of costimulatory molecules. 60 Blockade of costimulatory pathways to prevent GVHD is successful in animal models, but this approach has not yet been tested in large clinical trials. 2 In mouse models, in which genetic diff erences between donor and recipient strains can be tightly controlled, CD4+ cells induce acute GVHD to MHC class II diff erences and CD8+ cells induce acute disease to class I diff erences. 61, 62 In most HLA-identical HCTs, both CD4+ and CD8+ subsets respond to minor histocompatibility antigens and can cause GVHD in HLA-identical procedures.
Regulatory T cells can suppress proliferation of conventional T cells and prevent GVHD in animal models when added to donor grafts containing conventional T cells, 63 but use of regulatory T cells in clinical acute GVHD will need enhanced techniques to identify and expand them. Natural killer T-cell 1.1+ subsets from the host and donors have also been shown to modulate acute GVHD. 64 In a clinical trial of total lymphoid irradiation (as conditioning), GVHD was reduced signifi cantly and host natural killer T-cell function was amplifi ed. 65 Activation of immune cells results in rapid intracellular biochemical cascades that induce transcription of genes for many proteins, including cytokines and their receptors. T-helper 1 cytokines (interferon γ, interleukin 2, and TNFα) are released in large amounts during acute GVHD. Production of interleukin 2 by donor T cells remains the main target of many current clinical therapeutic and prophylactic approaches to GVHD, such as cyclosporine, tacrolimus, and monoclonal antibodies directed against this cytokine and its receptor. 9 However, emerging data indicate an important role for interleukin 2 in the generation and maintenance of CD4+CD25+ regulatory T cells, suggesting that prolonged interference with this cytokine could unintentionally stop development of long-term tolerance after allogeneic HCT. 66 Interferon γ has many functions and can either amplify or reduce GVHD. 67, 68 It could boost disease by increasing expression of molecules such as chemokine receptors, MHC proteins, and adhesion molecules; it also raises the sensitivity of monocytes and macrophages to stimuli such as lipopolysaccharide and accelerates intracellular cascades in response to these stimuli. 69 Early polarisation of donor T cells so that they secrete less interferon γ and more interleukin 4 can also attenuate experimental acute GVHD. 70 Interferon γ might amplify GVHD by direct damage to epithelium in the gastrointestinal tract and skin and by induction of immunosuppression by generation of nitric oxide. 71 By contrast, this cytokine could suppress GVHD by hastening apoptosis of activated donor T cells. 68, 72 This complexity means manipulation of interferon γ could have diverse eff ects in vivo, making the cytokine a challenging target with respect to therapeutic intervention.
Interleukin 10 has a key role in suppression of immune responses, and clinical data suggest it might regulate acute GVHD. 17 Transforming growth factor β, another suppressive cytokine, can subdue acute GVHD but exacerbate chronic disease. 73 Thus, timing and duration of secretion of any given cytokine could establish the specifi c eff ects of that molecule on GVHD severity. The third eff ector phase of the graft-versus-host process (fi gure 3) is a complex cascade of cellular mediators (such as cytotoxic T lymphocytes and natural killer cells) and soluble infl ammatory agents (eg, TNFα, interferon γ, interleukin 1, and nitric oxide). 2, 29 These molecules work synergetically to amplify local tissue injury and further promote infl ammation and target tissue destruction.
The cellular eff ectors of acute GVHD are mainly cytotoxic T lymphocytes and natural killer cells. 49 Cytotoxic T lymphocytes that prefer to use the Fas and FasL pathway of target lysis seem to predominate in GVHD liver damage (hepatocytes express large amounts of Fas) whereas cells that use the perforin and granzyme pathways are more important in the gastrointestinal tract and skin. 2, 74 Chemokines direct migration of donor T cells from lymphoid tissues to the target organs in which they cause damage. Macrophage infl ammatory protein 1α and other chemokines (such as CCL2-CCL5, CXCL2, CXCL9, CXCL10, CXCL11, CCL17, and CCL27) are overexpressed and enhance homing of cellular eff ectors to target organs during experimental GVHD. 75 Expression of integrins, such as α4β7 and its ligand MADCAM1, is also important for homing of donor T cells to Peyer's patches during intestinal GVHD. 52, 76, 77 Microbial products such as lipopolysaccharide, which leak through damaged intestinal mucosa or skin, can stimulate secretion of infl ammatory cytokines through Toll-like receptors. 49, 78 The gastrointestinal tract is especially susceptible to damage from TNFα, and the gastrointestinal tract has a major role in amplifi cation and propagation of the cytokine storm characteristic of acute GVHD. 49 TNFα can be produced by both donor and host cells and it acts in three diff erent ways: (1) it activates APCs and enhances alloantigen presentation; (2) it recruits eff ector cells to target organs via induction of infl ammatory chemokines; and (3) it directly causes tissue necrosis (as its name suggests).
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Prevention of GVHD
On the basis of evidence from animal models for the central role of T cells in initiation of GVHD, many clinical studies of T-cell depletion as prophylaxis for the disease were undertaken in the 1980s and 1990s. Three main depletion strategies were studied: (1) negative selection Most approaches showed substantial limitation of both acute and chronic GVHD. [83] [84] [85] Unfortunately, the lowest frequency of severe GVHD was off set by high rates of graft failure, relapse of malignant disease, infections, and Epstein-Barr virus-associated lymphoproliferative disorders. Negative-selection purging strategies with various antibodies against T cells achieved similar long-term results irrespective of the breadth of antibody specifi city. [86] [87] [88] Findings of one large registry study showed that purging techniques that used antibodies with broad specifi cities produced inferior leukaemia-free survival than standard immunosuppression in patients receiving unrelated donor transplants. 89 Several research groups have investigated partial T-cell depletion, either by elimination of specifi c T-cell subsets (eg, CD8+) or by titration of the dose of T cells present in the inoculum. [90] [91] [92] None of these approaches, however, has been shown convincingly to be the best strategy that enhances long-term survival.
Alemtuzumab is a monoclonal antibody that binds CD52, a protein expressed on a broad range of leukocytes including lymphocytes, monocytes, and dendritic cells. Its use in a phase II trial of GVHD prophylaxis lowered incidence of acute and chronic GVHD after reduced-intensity transplant. 93 In two prospective studies, patients who received alemtuzumab rather than methotrexate showed signifi cantly lower rates of acute and chronic GVHD, 94 but they had more infectious complications and higher rates of relapse, so no overall survival benefi t was recorded. Alemtuzumab might also contribute to graft failure when used with minimumintensity conditioning regimens. 95 An alternative strategy to T-cell depletion attempted to induce anergy in donor T cells by ex-vivo antibody blockade of costimulatory pathways before transplantation. Findings of a small study of this approach in patients undergoing haploidentical HCT was quite encouraging, but they have not yet been replicated. 96 Thus, the focus of most preventive strategies remains pharmacological manipulation of T cells after transplant.
Administration of antibodies against T cells in vivo as GVHD prophylaxis has also been tested extensively. The best studied drugs are anti-thymocyte globulin or anti-lymphocyte globulin preparations. These serum samples, which have high titres of polyclonal antibodies, are made by immunisation of horses or rabbits to thymocytes or lymphocytes, respectively. A complicating factor in establishing the role of these polyclonal serum samples in transplantation is the observation that even diff erent brands of the same class exert diverse biological eff ects. 97 However, the side-eff ects of anti-thymocyte globulin and anti-lymphocyte globulin infusions are similar across diff erent preparations and include fever, chills, headache, thrombocytopenia (from cross-reactivity to platelets), and, infrequently, anaphylaxis.
In retrospective studies, rabbit anti-thymocyte globulin reduced the frequency of GVHD in related-donor haemopoietic stem-cell transplant recipients without seeming to enhance survival. 98, 99 In patients receiving unrelated-donor haemopoietic stem cells, addition of anti-lymphocyte globulin to standard GVHD prophylaxis prevented severe GVHD eff ectively but did not result in better survival because of increased infections. 86 In a long-term follow-up study, however, pretransplant anti-thymocyte globulin provided signifi cant protection against extensive chronic GVHD and chronic lung dysfunction. 100 The primary pharmacological strategy to prevent GVHD is inhibition of the cytoplasmic enzyme calcineurin, which is important for activation of T cells. The calcineurin inhibitors cyclosporine and tacrolimus have similar mechanisms of action, clinical eff ectiveness, and toxic eff ects, including hypomagnesaemia, hyperkalaemia, hypertension, and nephrotoxicity.
9,101 Serious side-eff ects include transplant-associated thrombotic microangiopathy and neurotoxic eff ects that can lead to premature discontinuation. Although clinically similar to thrombotic thrombocytopenic purpura, transplant-associated thrombotic micro angio pathy does not respond reliably to therapeutic plasmapheresis, carries a high mortality rate, and removal of the off ending agent does not always result in improvement. 102 Posterior reversible encephalopathy syndrome includes mental status changes, seizures, neurological defi cits, and characteristic fi ndings on MRI; this syndrome has been seen in 1-2% of patients undergoing HCT and taking calcineurin inhibitors. 103 Side-eff ects of these drugs fall as the dose is tapered, usually 2-4 months after transplantation.
Calcineurin inhibitors are usually administered in combination with other immunosuppressants, such as methotrexate, which is given at low doses in the early post-transplant period. 9, 101 The toxic eff ects of methotrexate (neutropenia and mucositis) have led some investigators to replace it with mycophenolate mofetil. In a prospective randomised trial, patients who received mycophenolate mofetil as part of GVHD prophylaxis had signifi cantly less severe mucositis and more rapid neutrophil engraftment than did those who received methotrexate. 104 Frequency and severity of acute GVHD was similar between the two groups, but the study closed early because of superiority of the mycophenolate mofetil arm with respect to reduced mucositis and speed of haemopoietic engraftment. A desire for faster neutrophil engraftment has led to use of mycophenolate mofetil in umbilical-cord blood transplants for which graft failure is a major concern. 105 This drug is also sometimes used after reduced-intensity conditioning regimens for similar reasons. 106, 107 Sirolimus is an immunosuppressant that is structurally similar to tacrolimus but does not inhibit calcineurin. In phase II trials, sirolimus was very eff ective in combination with tacrolimus;
108,109 the drug damages endothelial cells, however, and it might enhance transplant-associated thrombotic microangiopathy, which is associated with calcineurin inhibitors. 110 The combination of tacrolimus and sirolimus is currently being compared in a large randomised multicentre trial.
Reduced-intensity conditioning regimens attempt to suppress the host immune system suffi ciently so that donor T cells can engraft and then ablate the lymphohaemopoietic compartment of the recipient. The term non-myeloablative is therefore somewhat misleading. Reduced-intensity conditioning regimens diminish tissue damage and lead to decreased amounts of infl ammatory cytokines, which are important in the initiation of GVHD pathophysiology; this eff ect could account for the reduced frequency of severe GVHD after reduced-intensity conditioning versus full-intensity conditioning used in historical controls. 53, 54, 93, 111 Onset of acute GVHD can be delayed after reduced-intensity conditioning until after day 100, however, and acute disease could present simultaneously with elements of chronic GVHD (known as overlap syndrome).
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Treatment of acute GVHD
GVHD fi rst develops, generally, in the second month after HCT during calcineurin-based prophylaxis. 114 Steroids, with their potent anti-lymphocyte and anti-infl ammatory activity, are the gold standard for treatment of GVHD. Many centres treat mild GVHD of the skin (grade I) with topical steroids alone, but for more severe disease and any degree of visceral GVHD involvement high-dose systemic steroids are usually initiated. Administration of steroids results in complete remission in less than half of patients, 115 and more severe GVHD is less likely to respond to treatment. 116 In a prospective randomised study, addition of anti-thymocyte globulin to steroids as primary treatment did not increase the response rate. 116 In a retrospective study, use of anti-thymocyte globulin in patients who showed early signs of steroid resistance was benefi cial, 115 but not all study fi ndings show such benefi t, and this antibody preparation is not used as standard because of raised infection risks. 100, 117 Infusion of mesenchymal stromal cells-expanded in culture either from the original HCT donor or from a third party-is a promising approach, which produced 55% complete responses in a phase II study of patients with steroid-resistant GVHD. 57 An increasingly frequent treatment for GVHD is extracorporeal photopheresis. During this procedure, the patient's white blood cells are gathered by apheresis, incubated with the DNA-intercalating agent 8-methoxypsoralen, exposed to ultraviolet light, and returned to the patient. Extracorporeal photopheresis is known to induce cellular apoptosis, which has strong anti-infl ammatory eff ects in several systems, including prevention of rejection of solid organ grafts. 118 Work done in animals shows that extracorporeal photopheresis reverses acute GVHD by increasing the number of regulatory T cells. 119 Data from a phase II clinical study of steroid-dependent or steroid-refractory GVHD showed resolution of disease in most patients, with 50% long-term survival in this very-high-risk group. 120 Randomised multicentre studies of this approach are needed to establish its place in management of acute GVHD.
Another strategy to treat GVHD is blockade of the infl ammatory cytokine TNFα. TNFα can activate APCs, recruit eff ector cells, and cause direct tissue damage (see Pathophysiology of acute GVHD). 121 Data from a phase II trial of etanercept (solubilised TNFα receptor 2) showed signifi cant eff ectiveness of the drug when added to systemic steroids as primary treatment for acute GVHD. 70% of patients had complete resolution of all GVHD symptoms within 1 month, with 80% complete responses in the gastrointestinal tract and skin. The researchers also reported that concentrations in plasma of TNFα receptor 1 were a signifi cant biomarker for clinical GVHD.
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Treatment of chronic GVHD
By contrast with acute GVHD, the pathophysiology of chronic GVHD remains poorly understood and the disease is treated with various immunosuppressive agents. The response of chronic GVHD to treatment is unpredictable, and mixed responses in diff erent organs can take place in the same patient. Confounding variables such as infection and comorbidities also make responses hard to measure. Use of corticosteroids (with or without a calcineurin inhibitor) is the standard of care, but fi ndings of a randomised trial of more than 300 patients with chronic GVHD noted no diff erence between cyclosporine plus prednisone versus prednisone alone. 123 Chronic immunosuppressants, especially those containing steroids, are highly toxic and result in deaths from infection. Many second-line treatments have been studied, but none has achieved widespread acceptance. As mentioned in the Treatment of acute GVHD section, extracorporeal photopheresis shows some promise, with relevant response rates in high-risk patients. The best responses were seen in skin, liver, oral mucosa, eye, and lung. 124 This observation is especially pertinent because lung GVHD has the potential to be a particularly devastating complication of chronic GVHD. Inhaled high-dose steroids, when added to existing immunosuppressant regimens, have stabilised the pulmonary function of patients with bronchiolitis obliterans in a small trial. 125 If other treatments fail, lung transplantation might be the only remaining therapeutic option.
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Essential supportive care in GVHD patients
Meticulous supportive care is vital for patients with both acute and chronic GVHD owing to the extended duration of immunosuppressive regimens and because the many drugs administered could have synergistic toxic eff ects. Such care includes extensive infectious prophylaxis, early interventions in cases of suspected infections, and prophylaxis against non-infectious side-eff ects of drugs (table) . These complications usually need rapid responses to prevent serious or irreversible damage and are best handled by close collaboration between the primary doctor and the transplant specialist.
All patients should receive at least fl uconazole as prophylaxis against fungal infections. Invasive moulds, especially aspergillus, are typical with prolonged steroid use. 127 Prophylaxis with voriconazole or posaconazole should be considered for these individuals. Usual sites of infection are the lungs, sinuses, brain, and skin, 128 and serial galactomannan assays could aid in early detection. 129 Candida can cause lesions in the lung, liver, and spleen, which might need screening with ultrasonography. Pneumocystis is another opportunistic infection that should receive cotrimoxazole (bactrim) prophylaxis. 130 Viral infections are frequent in people with GVHD. Cytomegalovirus causes interstitial pneumonia and gastritis. Patients who are at risk should have their blood monitored several times a month. Techniques that directly detect virus should be undertaken, such as cytomegalovirus PCR or pp65 antigen, and evidence of increased viral load should prompt pre-emptive treatment with ganciclovir or foscarnet before clinical manifestations of disease. Shingles is not uncommon and aciclovir prophylaxis could be benefi cial. 131 Patients and caregivers should receive vaccinations against infl uenza, and treatment with neuraminidase inhibitors is recommended in the event of infl uenza infection. Patients with GVHD sometimes have IgG2 and IgG4 subclass defi ciencies despite usual amounts of lgG, making them susceptible to infections with encapsulated organisms. Treatment of severe hypo gamma globu linaemia with intravenous immunoglobulin is standard in many centres, 134 but the level that triggers replacement varies considerably between transplant specialists. Supporting evidence for routine use of intravenous immunoglobulin as prophylaxis is scarce, 135 but patients should receive routine prophylaxis (penicillin or its equivalent) because of increased risk for streptococcal sepsis. 136 Pneumococcal conjugate and Haemophilus infl uenzae vaccine might provide additional protection and are recommended for all patients, including those with chronic GVHD. 130, 137 The sites of any indwelling catheters should be assessed regularly and early treatment of a suspected infection initiated. Early signs or symptoms of septic shock, such as shaking chills or low blood pressure, need prompt assessment with chest radiography, CT scan, or both, blood culture, and treatment with broad-spectrum antibiotics because shock can progress rapidly in these patients.
Chronic immunosuppressant treatment has many toxic eff ects. Diabetes (which further increases risks for infection), muscle weakness, osteoporosis, avascular necrosis (usually requiring joint replacement), and other cushingoid features are typical with chronic steroid use. Frequent monitoring of blood glucose and screening of bone density are recommended, and treatment includes insulin, calcium, vitamin D, and bisphosphonates. 138, 139 Calcineurin inhibitors frequently cause renal im pairment, hypertension, and neurological paraesthesias. Standard supportive care includes blood pressure monitoring, assessment of renal function, and monitoring of drug concentrations in blood, which should be maintained within therapeutic ranges. To prevent renal dysfunction, most centres recommend vigorous oral outpatient hydration. Some patients are unable to tolerate calcineurin inhibitors and need diff erent immunosuppressive drugs altogether.
Cytopenias sometimes require treatment with growth factors such as granulocyte-colony-stimulating factor or cessation of the off ending agent. These approaches should always be taken in close consultation with a transplant specialist.
Future directions
As allogeneic transplantation becomes an increasingly attractive therapeutic option, need for novel approaches to GVHD has accelerated. The number of patients receiving transplants from unrelated donors is expected to double in the next 5 years, substantially boosting the population of patients with GVHD.
The advent of reduced-intensity conditioning regimens has diminished transplant-related mortality and lengthened the period during which acute GVHD can develop (many new cases present up to day 200), and need for close monitoring of individuals in this period has risen. Patients have typically returned to the care of their primary haematologists by this time, increasing the need for these doctors to collaborate with transplant specialists in the management of GVHD and its complications.
Identifi cation of biomarkers for GVHD with diagnostic (and possibly prognostic) signifi cance might eventually make treatment of GVHD pre-emptive rather than prophylactic. Cellular component therapies-such as regulatory T cells that have been expanded ex vivo-will also enter clinical trials in the near future, but the extensive infrastructure needed for such approaches will probably restrict their use initially to large academic centres, intensifying need for close communication between transplant specialists and referring haematologists.
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